Showing results (11-20 of 61) with videos related to

Sort By:
Pageof 7
European Journal of Haematology|August 22, 2003
Fas ligand is not constitutively expressed in low-grade B-cell lymphoma and B-lymphoblastoid cellsCarsten Grüllich, Manfred Richter, Sebastian Exner, et al.
Leukemia & Lymphoma|August 9, 2005
The death receptor pathway is not involved in alloreactive T-cell induced mitochondrial membrane permeabilityCarsten Grüllich, Suzanne McGoldrick, Robert Zeiser, et al.
BMC Research Notes|July 27, 2015
Steroid responsive encephalopathy associated with autoimmune thyroiditis following ipilimumab therapy: a case reportDavid Carl, Carsten Grüllich, Steffen Hering, et al.
Clinical Genitourinary Cancer|March 14, 2016
Local Recurrence After Curative Surgical Treatment of Renal Cell Cancer: A Study of 91 PatientsYueJun Du, Carsten Grüllich, Boris Hadaschik, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 10, 2009
A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoetic cell transplantation: the feasibility of deescalationHartmut Bertz, Alexandros Spyridonidis, Ralph Wäsch, et al.
Journal of Cancer Research and Clinical Oncology|August 21, 2020
Systemic treatment of advanced/metastatic renal cell carcinoma in the context of SARS-CoV-2 pandemic: recommendations from the interdisciplinary working group for renal tumors (IAG-N)Philipp Ivanyi, Carsten Grüllich, Nils Kroeger, et al.
Future Oncology (London, England)|May 20, 2017
The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscapePeter J Goebell, Christian Doehn, Carsten Grüllich, et al.
Urologic Oncology|July 6, 2014
The tyrosine kinase inhibitor nilotinib has antineoplastic activity in prostate cancer cells but up-regulates the ERK survival signal-Implications for targeted therapiesMeike Schneider, Nina Korzeniewski, Konstanze Merkle, et al.
Neoplasia (New York, N.Y.)|December 16, 2014
Harnessing the p53-PUMA axis to overcome DNA damage resistance in renal cell carcinomaXiaoguang Zhou, Yanis Tolstov, Aysenur Arslan, et al.
Urologic Oncology|June 21, 2016
Survival and prognostic factors of patients with renal cell cancer with bone metastasis in the era of targeted therapy: A single-institution analysisYueJun Du, Sascha Pahernik, Boris Hadaschik, et al.
Pageof 7